A5045108507- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Cancer survivorship and care
- Gastric Cancer Management and Outcomes
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Venous Thromboembolism Diagnosis and Management
- Palliative Care and End-of-Life Issues
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Patient-Provider Communication in Healthcare
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Central Venous Catheters and Hemodialysis
- Neutropenia and Cancer Infections
- Nutrition and Health in Aging
- Optimism, Hope, and Well-being
- Acute Myocardial Infarction Research
- Family Support in Illness
- Thyroid Cancer Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
Central University Hospital of Asturias
2016-2025
Instituto de Investigación Sanitaria del Principado de Asturias
2019-2025
Universidad de Oviedo
2023-2024
Gobierno del Principado de Asturias
2022-2023
University of the Basque Country
2020-2022
Hospital Universitario Virgen de la Arrixaca
2015
Hospital Universitario Virgen Macarena
2015
To validate a prognostic score predicting major complications in patients with solid tumors and seemingly stable episodes of febrile neutropenia (FN). The definition clinical stability implies the absence organ dysfunction, abnormalities vital signs, infections.We developed Clinical Index Stable Febrile Neutropenia (CISNE), six explanatory variables associated serious complications: Eastern Cooperative Oncology Group performance status ≥ 2 (2 points), chronic obstructive pulmonary disease (1...
Nutritional deficiency is a common medical problem that affects 15–40% of cancer patients. It negatively impacts their quality life and can compromise treatment completion. Oncological therapies, such as surgery, radiation therapy, drug therapies are improving survival rates. However, all these treatments play role in the development malnutrition and/or metabolic alterations patients, induced by tumor or its treatment. assessment patients necessary at time diagnosis throughout treatment, so...
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a complex family of tumors widely variable clinical behavior. The World Health Organization (WHO) 2010 classification provided valuable tool to stratify (NENs) in three prognostic subgroups based on the proliferation index. However, substantial heterogeneity remains within these subgroups, and simplicity sometimes entails an ambiguous imprecise stratification. purpose our study was evaluate impact histological differentiation WHO...
PURPOSE Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression targeted agents (TAs). We investigated the efficacy safety of lenvatinib in patients with previously treated GEP-NETs. PATIENTS AND METHODS This was a multicenter, single-arm, open-label, phase II trial two parallel cohorts (ClinicalTrials.gov identifier: NCT02678780 ) involving 21 institutions...
A cancer diagnosis can have a substantial impact on patient’s mental health and quality of life. The aim this study was to investigate the prevalence fatigue, emotional distress, uncertainty examine predictive value they life advanced patients. prospective, multicenter conducted between February 2020 May 2021 individuals diagnosed with an advanced, unresectable neoplasm prior initiating systemic antineoplastic treatment. Participants completed questionnaires quantify disease uncertainty,...
Abstract Background Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role certain tumor sites remains unclear. This study sought to elucidate efficacy and safety [ 177 Lu]Lu-DOTATATE NENs with different locations evaluate effect origin, bearing mind other prognostic variables. Advanced overexpressing somatostatin receptors (SSTRs) on functional imaging, any grade or location, treated at 24...
Abstract Single immune checkpoint blockade in advanced neuroendocrine neoplasms (NENs) shows limited efficacy; dual may improve treatment activity. Dune (NCT03095274) is a non-randomized controlled multicohort phase II clinical trial evaluating durvalumab plus tremelimumab activity and safety NENs. This study included 123 patients presenting between 2017 2019 with typical/atypical lung carcinoids (Cohort 1), G1/2 gastrointestinal 2), pancreatic 3) G3 gastroenteropancreatic (GEP) 4) NENs; who...
The study aimed to identify predictors of overall 30-day mortality in cancer patients with pulmonary embolism including suspected (SPE) and unsuspected (UPE) events. Secondary outcomes included 30- 90-day major bleeding venous thromboembolism (VTE) recurrence. cohort 1033 consecutive from the multicentre observational ambispective EPIPHANY (March 2006–October 2014). A subgroup 497 prospectively assessed for were subclassified into three work-up scenarios (SPE, truly asymptomatic UPE...
PURPOSE Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from is heterogeneous. The aim current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients. PATIENTS AND METHODS We extracted data Spanish Group Neuroendocrine Endocrine Tumors Registry (R-GETNE). Patient eligibility criteria included GEP...
The phase III ToGA trial established cisplatin, fluoropyrimidine and trastuzumab as the standard treatment in HER2-positive advanced gastric cancer (AGC). However, demonstrated HER2-negative AGC, oxaliplatin-based regimens could improve tolerance remaining effective. aim of this was to explore potential activity safety capecitabine, oxaliplatin (XELOX) patients with HER-2 positive cancer. We conducted a multicentre, prospective, non-randomised, non-controlled, open-label national (Spanish)...
Background Breast cancer is one of the most prevalent diseases in women. Prevention and treatments have lowered mortality; nevertheless, impact diagnosis treatment continue to all aspects patients’ lives (physical, emotional, cognitive, social, spiritual). Objective This study seeks explore experiences different stages women with breast go through by means a patient journey. Methods qualitative which 21 or survivors were interviewed. Participants recruited at 9 large hospitals Spain...
BackgroundSequential nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) (nab-P/Gem-mFOLFOX) showed a good safety clinical profile in metastatic pancreatic ductal adenocarcinoma (mPDAC) the phase I SEQUENCE trial.MethodsThe efficacy of sequential nab-P/Gem-mFOLFOX was compared with standard (nab-P/Gem) as first-line treatment multi-institutional, randomized, open-label, II trial patients untreated mPDAC. We randomly assigned 1:1 ratio...
Abstract In cancer patients, psychological distress, which encompasses anxiety, depression, and somatization, arises from the complex interplay of emotional behavioral reactions to diagnosis treatment, significantly influencing their functionality quality life. The aim was investigate factors associated with distress in patients. This prospective multicenter study, conducted by Spanish Society Medical Oncology (SEOM), included two cohorts patients (localized resected or advanced...
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. addition immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) a single-arm, phase II trial that recruited chemotherapy-naive, unresectable or metastatic G3 NENs gastroenteropancreatic (GEP) unknown origin. Patients received nivolumab 360 mg intravenously (iv) on day 1, carboplatin AUC 5 iv and etoposide 100 mg/m
Fear of cancer recurrence significantly impacts advanced patients, prompting emotional distress and increased healthcare utilization. This present study aims to analyze the fear among patients with undergoing systemic treatment its relationship sociodemographic, clinical, psychological factors. A multicenter cross-sectional was conducted in 15 oncology departments across Spain, involving locally advanced, unresectable, or metastatic eligible for treatment. Participants provided demographic...
The United States Food and Drug Administration Oncologic Drugs Advisory Committee voted (September 2024) against the use of programmed cell death protein-1 inhibitors for first-line treatment advanced or metastatic unresectable esophageal squamous carcinoma (ESCC) with a death-ligand 1 (PD-L1) expression Tumor Area Positivity (TAP) score < 1% combined positive due to an unfavorable benefit–risk profile observed across phase 3 CheckMate 648, KEYNOTE-590, RATIONALE-306 trials. Therefore, we...
<b><i>Introduction:</i></b> Pancreatic neuroendocrine neoplasms (PNENs) are uncommon with a wide spectrum of clinical behavior. The objective this study was to assess in large cohort patients the relative impact prognostic factors on survival. <b><i>Methods:</i></b> From June 2001 through October 2010, 1,271 were prospectively registered online (www.getne.org) at Spanish National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors...